Hydrogenology
Hydrogenology editorial study record

Oral hydrogen water prevents chronic allograft nephropathy in rats

Cardinal JS, Zhan J, Wang Y, Sugimoto R, Tsung A, McCurry KR, Billiar TR, Nakao A. · Kidney International. 2010;77(2):101–109.

PreclinicalH₂-rich waterPublished 2010
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Preclinical

Reported design

Controlled orthotopic kidney-transplant experiment with syngeneic and allogeneic rat groups

Research topic

Kidney and urinary health

Administration classification

H₂-rich water

Study result signal

Not reported in this record.

Outcome type

Not reported in this record.

Reported in the source

Methods at a glance

Population or model

Male Lewis donor kidneys transplanted into Lewis syngeneic or bilaterally nephrectomized Brown Norway allogeneic recipients; allograft recipients received short-course tacrolimus.

Sample

Initial groups were isograft plus regular water n=8, isograft plus H₂ water n=8, allograft plus regular water n=18 and allograft plus H₂ water n=17. Survival analyses used n=5, n=5, n=13 and n=12 respectively; other assays used smaller stated subsets.

Duration

From transplantation through day 60 tissue/function assessments or survival follow-up to death or day 150.

Intervention

From transplantation day 0, recipients drank hydrogen-rich water ad libitum; 500 mL batches were placed in glass drinking vessels twice daily. Allograft recipients also received tacrolimus 0.5 mg/kg intramuscularly on days 0–6.

Hydrogen form

H₂ dissolved in drinking water — H₂ only, not Brown's gas.

H₂ specification

Water was produced by dissolving H₂ at 0.4 MPa, stored in aluminum bags and reported above 0.6 mmol/L when supplied to the drinking vessels.

H₂ flow

Not applicable — drinking water, not gas inhalation.

O₂ delivered with H₂

No O₂ was co-delivered as part of the intervention.

Comparator

Transplant recipients drinking degassed regular water, with parallel syngeneic and allogeneic transplant groups.

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Proteinuria, creatinine clearance, body weight, graft failure and survival, histology and fibrosis, inflammatory-cell infiltration, oxidative-damage markers, cytokine/adhesion-molecule expression and MAP-kinase signaling.

Reported result

Hydrogen-rich water was associated with better allograft function, less chronic allograft injury, oxidative damage, inflammation and MAP-kinase activation, and longer survival: median survival exceeded 150 days versus 78 days with regular water. The study also reports that repeated long-term administration did not produce baseline circulating H₂ accumulation.

Results-extraction completeness

The complete open-archive publisher article, transplant and co-treatment protocols, initial and analysis-specific group sizes, water preparation and concentration, functional, survival, histological and molecular results, funding and conflict statement were checked.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Preclinical transplant model with different immunosuppression between syngeneic and allogeneic arms, assay-specific subsets, multiple outcomes and attrition reflected in smaller survival cohorts. Daily water consumption and ingested H₂ dose per rat were not reported. US federal grants and a Hydrogen Research Foundation award funded the study; all authors declared no competing interests.

Applies directly to

Rat kidney transplantation with short-course tacrolimus; it does not establish efficacy, safety or dosing in human transplant recipients.

Preliminary appraisal framework

Not reported in this record.

Preliminary risk-of-bias status

Not reported in this record.

Appraisal rationale

Not reported in this record.

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 19907413 · DOI: 10.1038/ki.2009.421

Publisher access

Open-archive complete publisher article.

Extraction basis

Complete Kidney International/ScienceDirect open-archive article and PubMed metadata; full-text extraction checked 9 August 2026.

Record revision

2026-08-10